Related Experiment Video

Updated: Apr 6, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

106

Alterations of the thrombin generation profile in rheumatoid arthritis

Anita Kern1,2, Attila Balog3, Sonja Dulic3

  • 1Department of Laboratory Medicine, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4, 1089, Budapest, Hungary. kern.anita1@gmail.com.

Journal of Thrombosis and Thrombolysis
|July 20, 2015
PubMed

Insights

Rheumatoid arthritis (RA) patients show faster thrombin generation velocity but reduced overall thrombin-producing potential. These coagulation system changes in RA are independent of therapy.

Area of Science:

  • Rheumatology
  • Hematology
  • Immunology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease causing cartilage and bone erosion.
  • Systemic inflammation in RA increases cardiovascular risks, including atherosclerosis.
  • The coagulation system's functionality is crucial for cardiovascular health.

Purpose of the Study:

  • To assess coagulation system functionality in RA patients using the Calibrated Automated Thrombogram (CAT) assay.
  • To investigate potential alterations in thrombin generation in RA.
  • To determine if observed changes correlate with RA therapy.

Main Methods:

  • Calibrated Automated Thrombogram (CAT) assay performed on RA patients and matched controls.
  • Analysis of CAT parameters including Velocity Index, Lag Time, Time to Peak, and Endogenous Thrombin Potential.
  • Comparison of coagulation parameters between RA patients and non-affected subjects.

Main Results:

  • RA patients exhibited increased Velocity Index (60 to 83 nM/min) and decreased Lag Time (3.47 to 2.83 min) and Time to Peak (6.98 to 5.58 min).
  • Endogenous Thrombin Potential was reduced in RA patients (1242 to 1108 nM min).
  • Observed coagulation alterations were not linked to specific RA therapies.

Conclusions:

  • Thrombin generation velocity is accelerated in RA patients.
  • The overall capacity for thrombin generation is diminished in RA.
  • These findings suggest a distinct prothrombotic state in RA, irrespective of treatment.

Keywords:
Biological therapyRheumatoid arthritisThrombin generationThrombosis

More Related Videos

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

7.4K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.1K
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
892
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.6K